07 November 2023
07 November 2023
At the BIO-Europe conference, Eli Lilly’s medical director discusses the far-reaching potential of its obesity-directed drug pipeline.
Orum’s drug has an FDA clearance for the therapy to enter Phase I testing in AML and myelodysplastic syndromes.
The updated service will aid healthtech businesses to use customised support based on development pace and budget allocations.
The manufacturing agreement intends to implement Galapagos' decentralised CAR-T manufacturing model.
NRx gained FDA fast track designation for the development of NRX-100 as part of a treatment for acute suicidality.
Zituvimet is a fixed-dose mixture of two active ingredients, sitagliptin and metformin hydrochloride.
Krazati received conditional marketing authorisation as a second-line treatment of KRAS-G12C mutated locally advanced or metastatic NSCLC.
Anastrozole was previously authorised to treat breast cancer in post-menopausal women.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
With only a few approved drugs currently available to treat DN by means other than regulation of blood pressure, innovator products that can treat by targeting other factors such as treatment of dyslipidemia, hypertension, or angiotensin inhibition, among others, is a key area of R&D in the DN space and is likely to pave the way for novel therapies in the near future. However, the treatment landscape is expected to remain unchanged due to limited availability of products in the late-stage pipeline currently.
Give your business an edge with our leading industry insights.
